Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) Operating Income (2022 - 2025)

Historic Operating Income for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to -$36.1 million.

  • Century Therapeutics' Operating Income fell 383.74% to -$36.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$33.9 million, marking a year-over-year increase of 7656.12%. This contributed to the annual value of -$138.1 million for FY2024, which is 573.81% up from last year.
  • Latest data reveals that Century Therapeutics reported Operating Income of -$36.1 million as of Q3 2025, which was down 383.74% from -$34.7 million recorded in Q2 2025.
  • In the past 5 years, Century Therapeutics' Operating Income ranged from a high of $74.2 million in Q1 2025 and a low of -$43.8 million during Q4 2023
  • For the 4-year period, Century Therapeutics' Operating Income averaged around -$27.7 million, with its median value being -$34.8 million (2024).
  • Its Operating Income has fluctuated over the past 5 years, first plummeted by 3139.37% in 2023, then skyrocketed by 33691.59% in 2025.
  • Quarter analysis of 4 years shows Century Therapeutics' Operating Income stood at -$33.3 million in 2022, then crashed by 31.39% to -$43.8 million in 2023, then grew by 14.8% to -$37.3 million in 2024, then increased by 3.11% to -$36.1 million in 2025.
  • Its Operating Income stands at -$36.1 million for Q3 2025, versus -$34.7 million for Q2 2025 and $74.2 million for Q1 2025.